TPGS/hyaluronic acid dual-functionalized PLGA nanoparticles delivered through dissolving microneedles for markedly improved chemo-photothermal combined therapy of superficial tumor

Peng, Tingting; Huang, Yao; Feng, Xiaoqian; Zhu, Chune; Shi, Yin; Wang, Xinyi; Bai, Xuequn; Pan, Xin; Wu, Chuanbin

doi:10.1016/j.apsb.2020.11.013

Cited by 37 publications

(29 citation statements)

References 60 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another member of the glycosaminoglycan family that has been applied to shield the surface of PLGA NPs is hyaluronic acid. This endogenous polymer provides a further important function, being a ligand of CD44 receptor, which can be exploited to target the membranes of some tumor cells that overexpress this receptor [ 105 , 106 ].…”

Section: Surface Modification Strategiesmentioning

confidence: 99%

Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines

El-Hammadi

Arias

2022

Nanomaterials

View full text Add to dashboard Cite

Therapeutics are habitually characterized by short plasma half-lives and little affinity for targeted cells. To overcome these challenges, nanoparticulate systems have entered into the disease arena. Poly(d,l-lactide-co-glycolide) (PLGA) is one of the most relevant biocompatible materials to construct drug nanocarriers. Understanding the physical chemistry of this copolymer and current knowledge of its biological fate will help in engineering efficient PLGA-based nanomedicines. Surface modification of the nanoparticle structure has been proposed as a required functionalization to optimize the performance in biological systems and to localize the PLGA colloid into the site of action. In this review, a background is provided on the properties and biodegradation of the copolymer. Methods to formulate PLGA nanoparticles, as well as their in vitro performance and in vivo fate, are briefly discussed. In addition, a special focus is placed on the analysis of current research in the use of surface modification strategies to engineer PLGA nanoparticles, i.e., PEGylation and the use of PEG alternatives, surfactants and lipids to improve in vitro and in vivo stability and to create hydrophilic shells or stealth protection for the nanoparticle. Finally, an update on the use of ligands to decorate the surface of PLGA nanomedicines is included in the review.

show abstract

Section: Surface Modification Strategiesmentioning

confidence: 99%

Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines

El-Hammadi

Arias

2022

Nanomaterials

View full text Add to dashboard Cite

show abstract

“…The encapsulated drugs in MNs with cross‐linked polymer as MNs matrix can be released after absorbing interstitial fluid, and show a relative slower drug release rate. [ 112 ] Biodegradable polymers, such as PLGA, [ 113,114 ] PLA, [ 115 ] and PCL, [ 116 ] also can used as the matrix materials for MNs. They cannot be dissolved or swelled in water.…”

Section: Materials and Classification Of Mnsmentioning

confidence: 99%

Recent Advances in Polymer Microneedles for Drug Transdermal Delivery: Design Strategies and Applications

Wang

Jiang

Aharodnikau

et al. 2022

Macromol. Rapid Commun.

View full text Add to dashboard Cite

In recent years, transdermal drug delivery based on microneedles (MNs) technology has received extensive attention, which offers a safer and painless alternative to hypodermic needle injections. They can pierce the stratum corneum and deliver drugs to the epidermis and dermis-structures of skin, showing prominent properties such as minimally invasiveness, bypassing first-pass metabolism, and can be self-administered. A range of materials has been used to fabricate MNs, such as silicon, metal, glass, and polymers. Among them, polymer MNs have gained increasing attention from pharmaceutical and cosmetic companies as one of the promising drug delivery methods. MN products have recently become available on the market, and some of them are under evaluation for efficacy and safety. This paper focuses on the current state of polymer MNs in drug transdermal delivery. The materials and methods for the fabrication of polymer MNs and their drug administration are described. The recent progress of polymer MNs for treatment of cancer, vaccine delivery, blood glucose regulation, androgenetic alopecia, obesity, tissue healing, myocardial infarction, and gout are reviewed. The challenges of MNs technology are summarized and the future development trend of MNs is also prospected.

show abstract

“…As delivery vehicles [ 7 ], nanoparticles not only provide a variety of delivery systems for many bioactive insoluble drugs [ 8 , 9 ] but can also protect the active drugs from degradation during blood circulation [ 10 ] to guarantee that more drug molecules are delivered to the targeted site [ 11 – 13 ]. Therefore, nanoparticles for tumor targeting have attracted the attention of many scholars [ 14 – 17 ]. In recent decades, both passive and active targeting strategies have been widely employed to achieve this aim.…”

Section: Introductionmentioning

confidence: 99%

Enhanced tumor accumulation and therapeutic efficacy of liposomal drugs through over-threshold dosing

Wang

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

Background Most intravenously administered drug-loaded nanoparticles are taken up by liver Kupffer cells, and only a small portion can accumulate at the tumor, resulting in an unsatisfactory therapeutic efficacy and side effects for chemotherapeutic agents. Tumor-targeted drug delivery proves to be the best way to solve this problem; however, the complex synthesis, or surface modification process, together with the astonishing high cost make its clinical translation nearly impossible. Methods Referring to Ouyang’s work and over-threshold dosing theory in general, blank PEGylated liposomes (PEG-Lipo) were prepared and used as tumor delivery enhancers to determine whether they could significantly enhance the tumor accumulation and in vivo antitumor efficacy of co-injected liposomal ACGs (PEG-ACGs-Lipo), a naturally resourced chemotherapeutic. Here, the phospholipid dose was used as an indicator of the number of liposomes particles with similar particle sizes, and the liposomes was labelled with DiR, a near-red fluorescent probe, to trace their in vivo biodistribution. Two mouse models, 4T1-bearing and U87-bearing, were employed for in vivo examination. Results PEG-Lipo and PEG-ACGs-Lipo had similar diameters. At a low-threshold dose (12 mg/kg equivalent phospholipids), PEG-Lipo was mainly distributed in the liver rather than in the tumor, with the relative tumor targeting index (RTTI) being ~ 0.38 at 72 h after administration. When over-threshold was administered (50 mg/kg or 80 mg/kg of equivalent phospholipids), a much higher and quicker drug accumulation in tumors and a much lower drug accumulation in the liver were observed, with the RTTI increasing to ~ 0.9. The in vivo antitumor study in 4T1 tumor-bearing mice showed that, compared to PEG-ACGs-Lipo alone (2.25 mg/kg phospholipids), the co-injection of a large dose of blank PEG-Lipo (50 mg/kg of phospholipids) significantly reduced the tumor volume of the mice by 22.6% (P < 0.05) and enhanced the RTTI from 0.41 to 1.34. The intravenous injection of a low drug loading content (LDLC) of liposomal ACGs (the same dose of ACGs at 50 mg/kg of equivalent phospholipids) achieved a similar tumor inhibition rate (TIR) to that of co-injection. In the U87 MG tumor-bearing mouse model, co-injection of the enhancer also significantly promoted the TIR (83.32% vs. 66.80%, P < 0.05) and survival time of PEG-ACGs-Lipo. Conclusion An over-threshold dosing strategy proved to be a simple and feasible way to enhance the tumor delivery and antitumor efficacy of nanomedicines and was benefited to benefit their clinical result, especially for liposomal drugs. Graphical Abstract

show abstract

TPGS/hyaluronic acid dual-functionalized PLGA nanoparticles delivered through dissolving microneedles for markedly improved chemo-photothermal combined therapy of superficial tumor

Cited by 37 publications

References 60 publications

Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines

Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines

Recent Advances in Polymer Microneedles for Drug Transdermal Delivery: Design Strategies and Applications

Enhanced tumor accumulation and therapeutic efficacy of liposomal drugs through over-threshold dosing

Contact Info

Product

Resources

About